RENOWNED UROLOGIST DR. GEORGE TURINI III, MD PRESENTS POSTER ON BEHALF OF AVADIM TECHNOLOGIES INC. AT LEADING UROLOGY INDUSTRY EVENT
Peer-Reviewed and Selected Poster Demonstrates Multi-Site Success of Theraworx® Technology
Asheville, NC (May 18, 2017)—Avadim Technologies Inc., the Bionome Therapies™ life sciences company, today announced that a peer-reviewed abstract demonstrating the success of its innovative microbiome friendly skin care formulation, Theraworx® Technology, was presented to urology professionals from around the world gathered in Boston, Mass. to gain access to groundbreaking research and innovative treatment options that raise the standard of care in treating urologic disease. Co-authored by renowned Urologist Dr. George Turini III, MD and Chief Medical Officer of Avadim Technologies Joseph F. Renzulli II MD, FACS, the poster showcases the impact that Theraworx® had in patients that utilized urinary catheters in eight out of eight hospitals that complied with the recommended clinical protocols.
“We were very excited to present our results to the American Urological Association at their Annual Scientific Meeting,” said Dr. George Turini III, MD. “Our poster findings showcase results in eight hospitals reported when Theraworx’® innovative Hygiene approach was used for insertion and maintenance of urinary catheters, utilizing Theraworx’® microbiome-friendly skin care formulation.”
Through its microbiome compliant approach, Theraworx® Technology is engineered to support the skin’s ecosystem, which proactively defends against hospital acquired conditions – dramatically enhancing quality of life for a lifetime. When the skin’s natural ecosystem, the microbiome, breaks down, it creates an environment that opens the door to disease and infection. Theraworx’® microbiome compliant formulation is a positive clinical approach that does not negatively affect the skin’s natural flora, which human beings depend on to stay alive. The clinical evidence confirms that Theraworx® patented protocols are addressing hospital acquired conditions in a urology setting.. This is an urgent need given that UTIs are the most common type of hospital-associated condition. Traditional methods like soap and water yield only 1% to 14% reduction rates, even with following fully compliant protocols.
“We are honored that Theraworx® Technology was recognized in front of such a prestigious roster of the world’s top urologists,” said Dr. Joseph F. Renzulli II MD, FACS, and Chief Medical Officer at Avadim Technologies. “We are confident that Avadim’s innovation in developing topical non-drug, non-systemic and affordable hygiene solutions will continue to significantly impact the health and well being of millions who suffer from urogenital complications, both across hospitals and the countless Americans who suffer from urinary infections everyday. Avadim is bucking the trend in proactively supporting topical immune health with therapies that don’t require a prescription and will be available over the counter.”
As CMO of Avadim, Dr. Renzulli leads Avadim Technologies’ clinical research efforts for its product line of topical bionome therapies.
For more information on Avadim Technologies Inc. or Theraworx® Technology, please visit https://avadimhealth.com/.
ABOUT AVADIM TECHNOLOGIES INC.
Based in Asheville, North Carolina, Avadim is the Bionome TherapiesTM life sciences company. Avadim has created a new health order by eradicating the existing “sick care” approach to deliver true “health care” through topical Bionome TherapiesTM engineered to restore the skin’s natural ecosystem – each with the potential to dramatically enhance the quality of life for a lifetime. People are accepting of today’s standard of care (get sick, treat & repeat) even though it’s inadequate and few companies have stepped up to challenge this simply unacceptable approach that has been in existence for decades. Avadim is the industry leader in delivering true microbiome compliance with effective outcomes. Microbiome compliance ensures the therapy does not negatively effect the colonization of the skin’s microorganisms that human beings depend on to stay alive.
Avadim Technologies Inc. Contacts:
David Fann, President
828.251.7111 Office
904.251.4910 Cell
[email protected]
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
[email protected]
Avadim Technologies Inc.
81 Thompson Street
Asheville, NC 28803
www.avadimhealth.com
Media Contact
Meghan Orencole
Kel & Partners
[email protected]
O: 617.904.9393, ext. 143
C: 857.753.3688
Investor Relations:
KCSA Strategic Communications
Valter Pinto
212.896.1254
[email protected]
www.kcsa.com